AVE Science & Technology Co

AVE Science & Technology Co FCF Margin

The Free Cash Flow Margin of AVE Science & Technology Co (688067.SS) as of Nov 18, 2026 is 16.66 %. In the previous year, Free Cash Flow Margin was 9.18 % — a change of 81.54% (higher).

FCF Margin

16.66 %

YoY

81.54%

Last updated:

Free Cash Flow Margin of AVE Science & Technology Co is 2025 16.66 % . Free Cash Flow Margin of AVE Science & Technology Co was 2024 9.18 % . It decreases by 81.54% higher compared to the previous year.

The AVE Science & Technology Co FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
15.27 CNY
Jan 1, 2019
19.80 CNY
Jan 1, 2020
19.49 CNY
Jan 1, 2021
12.66 CNY
Jan 1, 2022
4.34 CNY
Jan 1, 2023
9.10 CNY
Jan 1, 2024
9.18 CNY
Jan 1, 2025
16.66 CNY
The AVE Science & Technology Co FCF Margin history
YEARFCF MarginYoY
16.66 %+81.54%
9.18 %+0.83%
9.10 %+109.84%
4.34 %-65.74%
12.66 %-35.06%
19.49 %-1.52%
19.80 %+29.62%
15.27 %-188.92%
-17.18 %-330.29%
7.46 %+95.52%
3.81 %-119.87%
-19.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVE Science & Technology Co Stock analysis

What does AVE Science & Technology Co do? AVE Science & Technology Co., Ltd. generates revenue through the research, development, production, sale, and service of clinical testing and analysis instruments. Its main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables. These products are primarily sold to inspection departments within medical and health institutions in both domestic and overseas markets. The company serves healthcare facilities that require diagnostic equipment for laboratory testing and patient care. The firm's product portfolio targets healthcare institutions seeking advanced diagnostic tools for efficient clinical analysis. By focusing on specialized instruments like urine and stool analyzers, AVE Science & Technology addresses specific needs in medical testing departments. The company's domestic and international distribution channels ensure broad market access for its diagnostic solutions. AVE Science & Technology's revenue streams are derived from the sale of its comprehensive range of clinical testing instruments and related consumables. The company's domestic market presence and overseas sales contribute to its overall business performance. Its products support routine diagnostic procedures across various healthcare settings, driving consistent demand for its equipment and reagents. AVE Science & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVE Science & Technology Co stock

Free Cash Flow Margin of AVE Science & Technology Co is 16.66 % in 2025.

Free Cash Flow Margin of AVE Science & Technology Co changed from 9.18 % to 16.66 %, representing a 81.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin AVE Science & Technology Co since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's AVE Science & Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — AVE Science & Technology Co

All Key Metrics — AVE Science & Technology Co